Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/ALNYLAM-PHARMACEUTICALS-I-8322/news/Alnylam-Pharmaceuticals-Doses-First-Patient-in-Phase-1-Study-of-ALN-AGT-an-Investigational-RNAi-T-28685099/?utm_source=whatsapp&utm_medium=social&utm_campaign=share